Chemicals & Small Molecules

Robatumumab (Sch 717454) is a fully human anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody with antitumor and antiproliferative activity.Robatumumab is used in the study of ovarian cancer.

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL).

Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.

Drozitumab (PRO 95780) is a fully humanized antibody targeting the death receptor DR5 that shows anti-tumor activity against rhabdomyosarcoma, binds to the death receptor DR5 and induces apoptosis, and can be used in the study of triple-negative breast cancer.

Timolumab (BTT 1023), a fully human antibody targeting vascular adhesion protein-1 (VAP-1), attenuates fibrosis in a mouse model of liver injury and may be used to study primary sclerosing cholangitis.

Begelomab (SAND-26) is a murine monoclonal antibody targeting DPP-4/CD26. Begelomab can be used to study severe refractory inflammatory myopathies and drug-resistant acute graft-versus-host disease.

Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) with potential antitumor activity for the study of the anti-PD-1 inhibitor budigalimab in non-small cell lung cancer.

Zenocutuzumab (MCLA-128) is a humanized bispecific IgG1 antibody with Fab arms targeting the extracellular domains of HER2 and HER3[1].

Zansecimab (LY-3127804) is a monoclonal antibody targeting angiopoietin 2 (Ang 2) for the study of cardiovascular and immune diseases.